**Lupus nephritis and beyond: Kidney-intrinsic genetic risk for antibody deposition**

Irene Chernova¹ and Joe Craft²,³,⁴

¹Section of Nephrology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06520, USA
²Section of Rheumatology, Allergy, and Immunology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06520, USA
³Department of Immunobiology, Yale School of Medicine, New Haven, CT 06520, USA
⁴Correspondence: joseph.craft@yale.edu

https://doi.org/10.1016/j.xcrm.2021.100479

**SUMMARY**

Antibody deposition is a defining pathological feature of multiple kidney diseases including lupus nephritis. In this issue of *Cell Reports Medicine*, Jiang and colleagues¹ identify a novel genetic risk factor, *VANGL1*, which predisposes individuals toward antibody deposition via a kidney-intrinsic mechanism.

The kidney is the most commonly affected major organ in patients with the autoimmune disease systemic lupus erythematosus (SLE, lupus), with 10% of those afflicted progressing to end-stage kidney disease.² Although mechanisms of kidney damage remain incompletely understood, autoantibody deposition and inflammation with immune cell infiltration are hallmarks of the disease and serve as targets of most therapies for lupus nephritis (LN). Treatment has centered around broad immunosuppression with more recent treatments, e.g., belimumab, directed toward depletion of autoantibody-producing B cells.³ A deeper understanding of the drivers behind autoantibody deposition in lupus nephritis and other antibody-mediated kidney diseases is critically important to improving clinical care.

Multiple genetic risk factors, primarily HLA susceptibility in concert with common polymorphisms identified by tagging single nucleotide polymorphisms in gene regulatory regions, confer lupus susceptibility.⁴ Mutations leading to loss of gene function, such as C4 deficiency, which is strongly associated with SLE onset, by contrast are much less common culprits. The known genetic risk factors can be broadly subdivided into 3 gene categories: (1) those affecting the immune system, (2) genes affecting programmed cell death and autoantigens, and (3) kidney-expressed genes promoting intrarenal pathogenesis.⁵ First, dysregulation of both the innate and adaptive immune systems has been implicated in LN pathogenesis with variants in pattern recognition receptors, immune complex clearance, T and B lymphocyte activation all playing a role. Second, abnormalities in programmed cell death processes allow for the externalization of normally concealed antigens (e.g., nuclear proteins) and their recognition as non-self by the immune system. Notably, these two large categories involve extra-renal processes. The third, smaller category is comprised of intrarenal genes that fall into two subgroups: chemokine pathways that facilitate immune cell infiltration of the kidney⁶ and genes associated with co-morbidities such as hypertension that make the kidney more susceptible to injury overall.⁷,⁸

In this issue of *Cell Reports Medicine*, Jiang and colleagues describe a genetic risk factor that does not fall neatly into one of the above categories and bridges the gap between kidney-intrinsic and immune risk factors: a gene predisposing to antibody deposition in a kidney-intrinsic manner.¹ The authors identify an association between copy number variation of the gene *VANGL1* and lupus nephritis and characterize the same loss between the studied populations. The authors demonstrate that antibody deposition itself is insufficient to drive pathology and must be accompanied by a “second hit.” Together, these findings identify a genetic risk factor with likely broad applicability to numerous kidney diseases and an uncommon kidney-intrinsic mechanism.

While the study provides strong complementary human and mouse genetic approaches to define the role of *VANGL1*, there are some limitations and unaddressed questions ripe for future study. First, the association between *VANGL1* mutations and specific kidney disorders remains incompletely characterized. Importantly, the initial association with lupus nephritis that the authors describe was not observed in a validation cohort, potentially due to ethnic differences between the studied populations. The authors also describe a higher mutation prevalence in an indigenous group with higher rates of kidney disease, but the
kidney diseases affecting this population are heterogeneous, making it difficult to elucidate the specific role of VANGL1 while at the same time increasing the applicability of the group’s finding. Furthermore, this population had no association between mutation frequency and stage of chronic kidney disease. Future population studies will be essential to parse the associations between ethnicity, specific kidney disease etiologies, disease chronicity, and VANGL1. Next, the specifics of VANGL1 genetics and mechanism remain to be elucidated. How a deletion in intron 7 leads to alterations in protein structure is one such question, and the presence of a cryptic splice site postulated by the authors deserves further consideration. Access to biopsy data from patients with kidney disease who have intact VANGL1 or are hemizygous or homozygous for the deletion would be another crucial step toward understanding the contribution of this mutation to tissue pathology. Finally, experiments in well-established mouse models of kidney disease, particularly lupus nephritis, will be critical to defining the role Vangl1 has in maintaining kidney-intrinsic barrier defenses to antibody deposition. Overall, this study represents an important step forward in our understanding of the genetic, kidney-intrinsic risk factors for kidney disease and opens many avenues for investigation into the role of VANGL1 in human health and disease.

DECLARATION OF INTERESTS

The authors declare no competing interests.

REFERENCES

1. Jiang, S.H., Mercan, S., Papa, I., Moldovan, M., Walters, G.D., Koina, M., Fadia, M., Stanley, M., Lea-Henry, T., Cook, A., et al. (2021). Deletions in VANGL1 are a risk factor for antibody-mediated kidney disease. Cell Rep. Med. 2, 100475–1–100475–10.

2. Almaani, S., Meara, A., and Rovin, B.H. (2017). Update on Lupus Nephritis. Clin. J. Am. Soc. Nephrol. 12, 825–835.

3. Wise, L.M., and Stohl, W. (2020). Belimumab and Rituximab in Systemic Lupus Erythematosus: A Tale of Two B Cell-Targeting Agents. Front. Med. (Lausanne) 7, 303.

4. Langefeld, C.D., Ainsworth, H.C., Cunningham Graham, D.S., Kelly, J.A., Comeau, M.E., Marion, M.C., Howard, T.D., Ramos, P.S., Croker, J.A., Morris, D.L., et al. (2017). Transancestral mapping and genetic load in systemic lupus erythematosus. Nat. Commun. 8, 16021.

5. Munroe, M.E., and James, J.A. (2015). Genetics of Lupus Nephritis: Clinical Implications. Semin. Nephrol. 35, 396–409.

6. Liao, X., Pirapakaran, T., and Luo, X.M. (2016). Chemokines and Chemokine Receptors in the Development of Lupus Nephritis. Mediators Inflamm. 2016, 6012715.

7. Larsen, C.P., Beggs, M.L., Saeed, M., and Walker, P.D. (2013). Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy. J. Am. Soc. Nephrol. 24, 722–725.

8. Khan, S., Dar, S.A., Mandal, R.K., Jawed, A., Wahid, M., Panda, A.K., Lohani, M., Mishra, B.N., Akhter, N., and Haque, S. (2018). Angiotensin-Converting Enzyme Gene I/D Polymorphism Is Associated With Systemic Lupus Erythematosus Susceptibility: An Updated Meta-Analysis and Trial Sequential Analysis. Front. Physiol. 9, 1793.

9. Xu, Z., Duan, B., Croker, B.P., Wakeland, E.K., and Morel, L. (2005). Genetic dissection of the murine lupus susceptibility locus Sle2: contributions to increased peritoneal B-1a cells and lupus nephritis map to different loci. J. Immunol. 175, 936–943.